NCCN Guidelines for Patients® | Myelodysplastic Syndromes

67 NCCN Guidelines for Patients ® : Myelodysplastic Syndromes, 2018 Acronyms Acronyms AML acute myeloid leukemia ATG antithymocyte globulin CAM complementary and alternative medicine CBC complete blood count CML chronic myeloid leukemia CMML chronic myelomonocytic leukemia DLI donor lymphocyte infusion DNA deoxyribonucleic acid EPO erythropoietin ESA erythropoietin-stimulating agent FAB French-American-British FDA U.S. Food and Drug Administration FISH fluorescence in situ hybridization G-CSF granulocyte colony-stimulating factor GM-CSF granulocyte-macrophage granulocyte colony-stimulating factor GVHD graft-versus-host disease GVL graft-versus-leukemia HCT hematopoietic cell transplant HIV human immunodeficiency virus HLA human leukocyte antigen LDH lactate dehydrogenase IPSS International Prognostic Scoring System IPSS-R Revised International Prognostic Scoring System IST immunosuppressive therapy IV intravenous MDS myelodysplastic syndromes MDS/MPN myelodysplastic/myeloproliferative neoplasms mU/mL milliunits per milliliter PDGFRβ platelet-derived growth factor receptor beta TKI tyrosine kinase inhibitor TPO thrombopoietin TSH thyroid-stimulating hormone WHO World Health Organization WPSS WHO classification-based Prognostic Scoring System

RkJQdWJsaXNoZXIy MTE3MTE1